Forest Laboratories and Lundbeck announces positive results of Lexapro® phase III study in adolescents with major depression


The CDRS-R is a commonly used clinician-rated instrument that covers
17 symptom areas of depression relevant to adolescents, including
impaired schoolwork, difficulty having fun, social withdrawal,
physical complaints, and low self-esteem. Additional data from this
study are expected to be presented in 2008.

Researchers estimate that up to eight percent of adolescents are
affected by depression. However, FDA-approved treatment options for
this population are limited. Lexapro® is not currently approved by
the FDA for use in pediatric patients.

Subject to ongoing communication with the FDA and review of the full
study results for the just completed trial, Forest Laboratories, Inc.
intend to file in 2008 for an adolescent depression indication for
Lexapro®.

About the Study
A double-blind, parallel-group, placebo-controlled phase III study to
evaluate the safety and efficacy of Lexapro® in the treatment of
depressed adolescents, aged 12-17, was conducted in multiple centers
across the U.S. During the eight week study, 316 patients were
randomized to receive either Lexapro® 10-20 mg (n=158) or placebo
(n=158). The primary endpoint was change from baseline to week 8 on
the Children's Depression Rating Scale - Revised (CDRS-R) using last
observation carried forward (LOCF) approach. The study showed
statistically significant improvement in patients treated with
Lexapro® relative to placebo (p=0.022).

The trial also showed that Lexapro® was generally well-tolerated.
Overall premature discontinuation rates (all causes including adverse
events) were 19% for patients receiving Lexapro® and 15% for patients
receiving placebo.

Depression and Adolescents
Adolescent depression is characterized by persistent sadness and loss
of interest in usual activities.

Despite advances and progress in identifying and treating mental
disorders in adolescents, epidemiologic studies indicate that only
20-35 percent of depressed patients in this age group currently
receive treatment. Depression is a chronic disease that requires
medical attention and treatment, and if left untreated, may have
serious consequences.

For adolescents who suffer from depression, psychotherapy,
cognitive-behavior therapy, interpersonal therapy and medication play
an important role in the management of their illness. Patients on
antidepressant treatment should also be closely monitored by
healthcare providers, family members and other caregivers.

The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.

Lundbeck contacts


Investors:                    Media:

Jacob Tolstrup                Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79               +45 36 43 20 81



                      ________________________

Stock Exchange Release No 312 - 29 November 2007

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com

Attachments

Release No 312 in pdf format